Longevity research has come a long way since the early 2000s when studying aging was considered immoral. The Methuselah mouse prize in 2005 proved that extending the lifespan of a mouse could be achieved, leading to the belief that it could be done in humans as well. Since then, aging institutes, non-profit organizations, and academic institutions dedicated to longevity research have flourished. In recent years, there has been an explosion of interventions and technologies, ranging from small molecules to gene and cell therapies, gaining support from venture capitalists. Big pharma is also getting involved, creating longevity units to explore how these new technologies can be integrated into their pipelines. These longevity companies are not only focused on extending lifespan but also addressing diseases like cancer, Alzheimer's, osteoarthritis, and heart disease, making them attractive in the current regulatory and investment landscape.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode